Hims & Hers Announces Access to GLP-1 Injections, Passing Cost Savings Onto Customers
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Hims and Hers (HIMS) PT Raised to $24 at Canaccord Genuity
May 22, 2024 5:29 AM EDTCanaccord Genuity analyst Maria Ripps raised the price target on Hims and Hers (NYSE: HIMS) to $24.00 (from $20.00) while maintaining a Buy rating.
The analyst comments "On Monday, 5/20, Hims & Hers announced the addition of GLP-1 treatment to its portfolio of weight loss solutions, with prices... More
Citi Reiterates Buy Rating on Hims and Hers (HIMS)
May 20, 2024 11:49 AM EDTCiti analyst Daniel Grosslight reiterated a Buy rating and $16.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "As widely anticipated, HIMS launched its GLP-1 offering this morning, which we think will significantly increase the interest in its weight loss offering.... More
